A universal T cell vaccine for HIV-1

HIV-1 通用 T 细胞疫苗

• 批准号: G1001757/1
• 负责人: Tomas Hanke
• 金额: $ 168.55万
• 依托单位: University of Oxford
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2011
• 资助国家: 英国
• 起止时间: 2011 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G1001757%2F1
• 关键词: universal; cell; vaccine; HIV

HIV infection and AIDS continues to spread in a virtually uncontrolled manner. The best and possibly only hope to change this alarming situation is a safe, effective, accessible protective vaccine. Arguably the biggest challenge in developing such a vaccine is enormous HIV variability, which dwarfs that of almost any other infection. However, all parts of the virus cannot easily change. To remain alive, HIV has to keep some smaller regions of its proteins more or less constant. We have taken an advantage of this and constructed a candidate vaccine designed specifically to overcome HIV variability by focusing the body defences on the conserved regions of the virus, i.e. the Achilles heel of HIV. Here, we are proposing to build on and extend our ongoing vaccine development effort and, if successful, assemble a strong case for further evaluation of this vaccination strategy in larger scale and expensive field efficacy studies.

艾滋病毒感染和艾滋病继续以几乎不受控制的方式传播。最好的，甚至可能只希望改变这种令人震惊的情况是一种安全，有效，易于使用的防护疫苗。可以说，开发这种疫苗的最大挑战是巨大的艾滋病毒变异性，这使几乎所有其他感染的变异都相形见war。但是，病毒的所有部分都无法轻易改变。为了保持活力，艾滋病毒必须或多或少地保持其蛋白质的一些较小区域。我们已经利用了这一点，并建造了一种专门为克服艾滋病毒变异性而设计的候选疫苗，通过将身体防御物集中在病毒的保守区域，即HIV的致命弱点。在这里，我们建议以大规模和昂贵的现场效力研究进行进一步评估这种疫苗接种策略的有力案例，以进一步评估这种疫苗接种策略。